Latest & greatest articles for risperidone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on risperidone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on risperidone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for risperidone

41. Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: a randomised controlled trial. (Abstract)

Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: a randomised controlled trial. Aggressive challenging behaviour is frequently reported in adults with intellectual disability and it is often treated with antipsychotic drugs. However, no adequate evidence base for this practice exists. We compared flexible doses of haloperidol (a typical, first-generation antipsychotic drug), risperidone (an atypical, second (...) -generation antipsychotic), and placebo, in the treatment of this behaviour.86 non-psychotic patients presenting with aggressive challenging behaviour from ten centres in England and Wales, and one in Queensland, Australia, were randomly assigned to haloperidol (n=28), risperidone (n=29), or placebo (n=29). Clinical assessments of aggression, aberrant behaviour, quality of life, adverse drug effects, and carer uplift (positive feelings about the care of the disabled person) and burden, together with total

2008 Lancet Controlled trial quality: predicted high

42. Cost-effectiveness and budget impact of long-acting risperidone in Portugal: a modeling exercise

Cost-effectiveness and budget impact of long-acting risperidone in Portugal: a modeling exercise Cost-effectiveness and budget impact of long-acting risperidone in Portugal: a modeling exercise Cost-effectiveness and budget impact of long-acting risperidone in Portugal: a modeling exercise Heeg B M, Antunes J, Figueira M L, Jara J M, Marques Teixeira J, Palha A P, Vaz Serra A, Buskens E, Caleo S, Gouveia-Pinto C, Van Hout B A Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness and budget impact of long-acting risperidone (LAR) as first-line treatment of schizophrenia compared with conventional haloperidol depot and oral risperidone. The authors concluded that treatment with LAR might be cost

2008 NHS Economic Evaluation Database.

43. Olanzapine and risperidone may improve neurocognition more than haloperidol in people with schizophrenia who continue treatment for 52 weeks

Olanzapine and risperidone may improve neurocognition more than haloperidol in people with schizophrenia who continue treatment for 52 weeks Olanzapine and risperidone may improve neurocognition more than haloperidol in people with schizophrenia who continue treatment for 52 weeks | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use (...) cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Olanzapine and risperidone may improve neurocognition more than haloperidol in people with schizophrenia who

2007 Evidence-Based Mental Health

44. Discontinuing risperidone results in relapse in children with autism spectrum disorders

Discontinuing risperidone results in relapse in children with autism spectrum disorders Discontinuing risperidone results in relapse in children with autism spectrum disorders | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Discontinuing risperidone results in relapse in children with autism spectrum disorders Article Text Therapeutics Discontinuing risperidone results in relapse in children with autism spectrum disorders Statistics from

2007 Evidence-Based Mental Health

45. Adding sarcosine, but not D-serine, to risperidone improves symptoms in people with acute phase schizophrenia

Adding sarcosine, but not D-serine, to risperidone improves symptoms in people with acute phase schizophrenia Adding sarcosine, but not D-serine, to risperidone improves symptoms in people with acute phase schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Adding sarcosine, but not D-serine, to risperidone improves symptoms in people with acute phase schizophrenia Article Text Therapeutics Adding sarcosine, but not D

2007 Evidence-Based Mental Health

46. Risperidone effectively increases rates of symptomatic remission of acute mania in people with bipolar disorder

Risperidone effectively increases rates of symptomatic remission of acute mania in people with bipolar disorder Risperidone effectively increases rates of symptomatic remission of acute mania in people with bipolar disorder | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Risperidone effectively increases rates of symptomatic remission of acute mania in people with bipolar disorder Article Text Therapeutics Risperidone effectively

2007 Evidence-Based Mental Health

47. Risperidone improves restricted, repetitive, and stereotyped behaviour in autistic children and adolescents

Risperidone improves restricted, repetitive, and stereotyped behaviour in autistic children and adolescents Risperidone improves restricted, repetitive, and stereotyped behaviour in autistic children and adolescents | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Risperidone improves restricted, repetitive, and stereotyped behaviour in autistic children and adolescents Article Text Therapeutics Risperidone improves restricted, repetitive

2007 Evidence-Based Mental Health

48. Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia Full Text available with Trip Pro

Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia Bounthavong M, Okamoto M P Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined three drug treatments for patients with schizophrenia. Specifically, a conventional antipsychotic, haloperidol (HAL), and two newer atypical antipsychotics, risperidone (RIS) and olanzapine (OLA). The dosages assumed were 15 mg/day

2007 NHS Economic Evaluation Database.

49. Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care Full Text available with Trip Pro

Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care Niaz O S, Haddad P M Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined the use of risperidone long-acting injection (RLAI), compared with conventional oral antipsychotics, for patients with schizophrenia. RLAI (50 mg) was administered once every 2 weeks. Type

2007 NHS Economic Evaluation Database.

50. Risperidone in long-term treatment for bipolar disorder. (Abstract)

Risperidone in long-term treatment for bipolar disorder. Risperidone, an atypical antipsychotic, is used to treat acute manic episodes, particularly when psychotic symptoms are present. Drugs used to treat mania are often continued as long-term treatment to prevent relapse. There is a need for evidence of the effectiveness and safety of risperidone as long-term treatment.To assess the randomised evidence for the efficacy and tolerability of risperidone compared with placebo or other active (...) contacted.Randomised trials comparing risperidone with placebo or other drug in long-term treatment for prevention of depressive or manic relapses.Not applicable.No randomised trials comparing risperidone with other treatments for the prevention of manic and depressive relapses were identified.There is a need for randomised controlled trials comparing risperidone and other treatments for the prevention of relapse in bipolar disorder. The trials should involve randomisation of treatment for relapse prevention

2006 Cochrane

51. Schizophrenia: risperidone and olanzapine increase time to discontinuation compared with quetiapine and ziprasidone Full Text available with Trip Pro

Schizophrenia: risperidone and olanzapine increase time to discontinuation compared with quetiapine and ziprasidone Schizophrenia: risperidone and olanzapine increase time to discontinuation compared with quetiapine and ziprasidone | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Schizophrenia: risperidone and olanzapine increase time to discontinuation compared with quetiapine and ziprasidone Article Text Therapeutics

2006 Evidence-Based Mental Health

52. Risperidone maintenance treatment increases time to symptom recurrence in young people with disruptive behaviour disorders

Risperidone maintenance treatment increases time to symptom recurrence in young people with disruptive behaviour disorders Risperidone maintenance treatment increases time to symptom recurrence in young people with disruptive behaviour disorders | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Risperidone maintenance treatment increases time to symptom recurrence in young people with disruptive behaviour disorders Article Text

2006 Evidence-Based Mental Health

53. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. Full Text available with Trip Pro

Clozapine alone versus clozapine and risperidone with refractory schizophrenia. The treatment of schizophrenia with multiple antipsychotic drugs is common, but the benefits and risks are not known.In a randomized, double-blind study, we evaluated patients with schizophrenia and a poor response to treatment with clozapine. The patients continued to take clozapine and were randomly assigned to receive eight weeks of daily augmentation with 3 mg of risperidone or with placebo. This course (...) of treatment was followed by an optional 18 weeks of augmentation with risperidone. The primary outcome was reduction in the total score for severity of symptoms on the Positive and Negative Syndrome Scale (PANSS). The secondary outcomes included cognitive functioning.A total of 68 patients were randomly assigned to treatment. In the double-blind phase, the mean total score for the severity of symptoms decreased from baseline to eight weeks in both the risperidone and the placebo groups

2006 NEJM Controlled trial quality: predicted high

54. Risperidone augmentation of clozapine: a critical review

Risperidone augmentation of clozapine: a critical review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 DARE.

55. A decision model to compare health care costs of olanzapine and risperidone treatment of schizophrenia in Germany

A decision model to compare health care costs of olanzapine and risperidone treatment of schizophrenia in Germany A decision model to compare health care costs of olanzapine and risperidone treatment of schizophrenia in Germany A decision model to compare health care costs of olanzapine and risperidone treatment of schizophrenia in Germany Beard A M, Maciver F, Clouth J, Ruther E Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED (...) . Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study compared the use of olanzapine with risperidone in the treatment of patients with an established history of schizophrenia. Type of intervention Treatment. Economic study type Cost-utility analysis. Study population The study population comprised a hypothetical cohort of patients currently

2006 NHS Economic Evaluation Database.

56. Risperidone improves severe tardive dyskinesia in people with schizophrenia Full Text available with Trip Pro

Risperidone improves severe tardive dyskinesia in people with schizophrenia Risperidone improves severe tardive dyskinesia in people with schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts (...) Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Risperidone improves severe tardive dyskinesia in people with schizophrenia Article Text Therapeutics Risperidone improves severe tardive dyskinesia in people with schizophrenia Free Rajiv Tandon , MD Statistics from Altmetric.com Bai Y

2005 Evidence-Based Mental Health

57. A comparison of olanzapine versus risperidone for the treatment of schizophrenia: a meta-analysis of randomised clinical trials

A comparison of olanzapine versus risperidone for the treatment of schizophrenia: a meta-analysis of randomised clinical trials A comparison of olanzapine versus risperidone for the treatment of schizophrenia: a meta-analysis of randomised clinical trials A comparison of olanzapine versus risperidone for the treatment of schizophrenia: a meta-analysis of randomised clinical trials Mudge M A, Davey P J, Coleman K A, Montgomery W, Croker V S, Mullen K, Castle D J CRD summary This review concluded (...) that olanzapine was superior to risperidone for a number of efficacy and safety variables, and these advantages may convey clinical relevance to certain aspects of schizophrenia. A lack of a systematic quality assessment and no details of the review methodology suggest that this conclusion should be treated with caution. Authors' objectives To compare the efficacy and safety of olanzapine with risperidone in the treatment of schizophrenia. Searching MEDLINE, EMBASE and the Cochrane Controlled Trials Register

2005 DARE.

58. Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs Full Text available with Trip Pro

Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated (...) (or atypical antipsychotics) for the treatment of schizophrenia. Each strategy comprised a first-line treatment, followed by alternative therapies if the patient did not respond to treatment. The three strategies were as follows. The risperidone strategy comprised initial treatment with long-acting risperidone, followed by a first alternative of olanzapine, a second alternative of clozapine, and a third alternative of depot haloperidol. The depot haloperidol strategy comprised initial treatment with depot

2005 NHS Economic Evaluation Database.

59. Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany

Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany Laux G, Heeg B M S, van Hout B A, Mehnert A Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The three treatment strategies investigated were first-line treatment with haloperidol depot, long-acting risperidone and oral olanzapine for patients with schizophrenia. Type of intervention Treatment. Economic study type Cost-effectiveness analysis and cost-utility analysis. Study

2005 NHS Economic Evaluation Database.

60. Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis

Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis De Graeve D, Smet A, Mehnert, Caleo S, Miadi-Fargier H, Mosqueda G J, Lecompte D, Peuskens J Record (...) Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study compared the following therapeutic strategies for patients with schizophrenia: first-line treatment with long-acting risperidone, 25 mg every 14 days (ambulatory care or hospital

2005 NHS Economic Evaluation Database.